Search

Your search keyword '"Lutrick, Karen"' showing total 161 results

Search Constraints

Start Over You searched for: Author "Lutrick, Karen" Remove constraint Author: "Lutrick, Karen"
161 results on '"Lutrick, Karen"'

Search Results

1. Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study

2. Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study

5. Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers

6. Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies

7. SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance--Respiratory Virus Transmission Network, November 2022-May 2023

8. Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18–64 Years: Results and Experience From a Randomized, Double-Blind Trial.

9. Perceived Hospital Stress, Severe Acute Respiratory Syndrome Coronavirus 2 Activity, and Care Process Temporal Variance During the COVID-19 Pandemic*

10. Severe Acute Respiratory Infection—Preparedness: Protocol for a Multicenter Prospective Cohort Study of Viral Respiratory Infections

11. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

12. 524: SEVERE ACUTE RESPIRATORY INFECTION – PREPAREDNESS (SARI-PREP): A MULTICENTER PROSPECTIVE STUDY

15. 925. Oseltamivir usage in community settings: data from a household transmission study

16. 2293. Examining social vulnerability and its effect on COVID-19 transmission in households

17. 2080. Reduced risk of SARS-CoV-2 infection among household contacts with hybrid immunity from recent COVID-19 vaccination and SARS-CoV-2 infection

18. 400. Predictors of Post-COVID Conditions after SARS-CoV-2 Infection in Adults Enrolled in a Multistate Household Transmission Study

19. 2082. Effectiveness of Bivalent mRNA Vaccines in Preventing SARS-CoV-2 Infection Among Children Aged 5-17 years: an Evaluation of Multicenter Prospective Cohorts, United States, September 2022 - January 2023

20. 2302. Transmissibility of SARS-CoV-2 by symptom: data from a case-ascertained household transmission study

21. 930. COVID-19 symptom and viral load rebound among individuals reporting nirmatrelvir/ritonavir use compared to propensity score matched individuals not taking COVID-19 treatment

22. Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals

23. Temporal Changes in Vaccine-Specific Willingness Across Race/Ethnicity Following Serious Adverse Event Reports

24. 'Dance for Your Health': Exploring Social Latin Dancing for Community Health Promotion

25. Determinants of de novo B cell responses to drifted epitopes in post-vaccination SARS-CoV-2 infections

26. Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5–11 Years in a Multisite Prospective Cohort Study, September 2021–September 2022

28. Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality

29. Parental Intentions and Perceptions Toward COVID-19 Vaccination Among Children Aged 4 Months to 4 Years--PROTECT Cohort, Four States, July 2021-May 2022

30. Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design

31. Household Transmission of Influenza A Viruses in 2021-2022

32. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years--PROTECT Cohort, July 2021-February 2022

33. Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses

34. Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study

35. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers-- Eight U.S. Locations, December 2020-March 2021

37. Cutting Edge: T Cell Responses to B.1.1.529 (Omicron) SARS-CoV-2 Variant Induced by COVID-19 Infection and/or mRNA Vaccination Are Largely Preserved

38. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers

39. Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study (Preprint)

41. Incidence of SARS‐CoV‐2 infection among COVID‐19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January–September 2021

42. COVID-19 vaccine perceptions and uptake in a national prospective cohort of essential workers

43. Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021

44. Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection

45. 524: SEVERE ACUTE RESPIRATORY INFECTION – PREPAREDNESS (SARI-PREP): A MULTICENTER PROSPECTIVE STUDY

46. 119: HOSPITAL STRESS AND CARE PROCESS TEMPORAL VARIANCE DURING THE COVID-19 PANDEMIC IN THE U.S.

47. Incidence of SARS-CoV-2 Infection among COVID-19 Vaccinated and Unvaccinated Healthcare Personnel, First Responders, and other Essential and Frontline Workers--- Eight U.S. Locations, January--September 2021

48. High Burden of COVID-19 among Unvaccinated Law Enforcement Officers and Firefighters

50. Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection

Catalog

Books, media, physical & digital resources